RT Journal Article
SR Electronic
A1 Summers, Jaye
T1 Baseline Features of Patients With RMS in Ocrelizumab Trials OPERA I and OPERA II
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 9
SP 14
OP 14
DO 10.1177/1559897715588475
UL http://mdc.sagepub.com/content/15/9/14.1.abstract
AB OPERA I and OPERA II tested the safety and efficacy of ocrelizumab in patients with relapsing multiple sclerosis. Patients were randomized to either ocrelizumab or interferon beta-1a. At baseline, patient demographics and disease characteristics appear consistent with the majority of patients with the relapsing type of the disease.